May 21, 2008 - Intellectual Property Provides Strong Position for Development of Therapy for Asthma- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti-inflammatory therapies, announced today that it had been granted a patent in the U.S. related to a fusion protein with potential applications for treating respiratory diseases. The patent (United States Patent 7,247,704) covers compositions of matter and uses of Aeriva™, a fusion protein that combines Secretory Leukocyte Protease Inhibitor (SLPI) and recombinant alpha 1-antitrypsin (rAAT)... [PDF] Arriva Pharmaceuticals' Press Release -
May 23, 2008
Arriva Pharmaceuticals Granted Fusion Protein Patent
May 21, 2008 - Intellectual Property Provides Strong Position for Development of Therapy for Asthma- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti-inflammatory therapies, announced today that it had been granted a patent in the U.S. related to a fusion protein with potential applications for treating respiratory diseases. The patent (United States Patent 7,247,704) covers compositions of matter and uses of Aeriva™, a fusion protein that combines Secretory Leukocyte Protease Inhibitor (SLPI) and recombinant alpha 1-antitrypsin (rAAT)... [PDF] Arriva Pharmaceuticals' Press Release -
